

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Ipilimumab

INITIATION – stage III or IV resectable melanoma

Prerequisites (tick boxes where appropriate)

The individual is currently on treatment with ipilimumab for neoadjuvant treatment of resectable stage IIIB, IIIC, IIID or IV melanoma and met all remaining criteria prior to commencing treatment

or

- The individual has resectable stage IIIB, IIIC, IIID or IV melanoma (excluding uveal) (see note)
- and The individual has not received prior funded systemic treatment in the perioperative setting for their stage IIIB, IIIC, IIID or IV melanoma
- and The individual has ECOG performance score 0-2
- and Treatment must be prior to complete surgical resection
- and Neoadjuvant ipilimumab must be administered in combination with nivolumab
- and Ipilimumab to be administered for maximum of two cycles prior to surgical resection

Note:

- a) Stage IIIB, IIIC, IIID or IV melanoma defined as per American Joint Committee on Cancer (AJCC) 8th Edition.
- b) Disease must be completely resectable and amenable to curative intent surgery, including stage IV disease.

INITIATION – renal cell carcinoma

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

The patient is currently on treatment with ipilimumab and met all remaining criteria prior to commencing treatment

or

- The patient has metastatic renal cell carcinoma
- and The patient is treatment naive
- and The patient has ECOG performance status 0-2
- and The disease is predominantly of clear cell histology
- and The patient has sarcomatoid histology
- or Haemoglobin levels less than the lower limit of normal
- or Corrected serum calcium level greater than 10 mg/dL (2.5 mmol/L)
- or Neutrophils greater than the upper limit of normal
- or Platelets greater than the upper limit of normal
- or Interval of less than 1 year from original diagnosis to the start of systemic therapy
- or Karnofsky performance score of less than or equal to 70

and

Ipilimumab is to be used at a maximum dose of 1 mg/kg for up to four cycles in combination with nivolumab

I confirm that the above details are correct:

Signed: Date: